Nanotechnology Research at Liverpool receives EU Consortium Funding

More than £645,000 has been awarded to researchers from the University of Liverpool’s Department of Molecular and Clinical Pharmacology for progressing the use of nano-enabled medical technologies. The project, led by Dr Marco Siccardi in collaboration with Dr Neill Liptrott, is part of the SAFE-N-MEDTECH consortium, a European H2020 NMBP (Nanotechnologies, Advanced Materials, Biotechnology and Advanced Manufacturing and Processing), which also involves 27 other organisations around Europe. Part of the research will be focused on the bio distribution and safety of Nano-enabled medical technologies in health as they relate to their use in humans.

The overall project aims are to build an open access platform of reference laboratories offering capabilities, expertise and services specifically related to the testing, evaluation, optimisation and marketing of nanotechnology enabled diagnostic medical devices throughout the products’ entire lifecycle.
Dr Siccardi, said: “The open access platform that will be developed is unique and will support the development of innovative nano-enabled medical technologies for prevention and treatment with potential benefits for both patients and the NHS. The project is based on exciting collaborative network in Europe, providing exceptional opportunities for future collaborations, through the application of cutting-edge research strategies. ”

Dr Liptrott, said “Nanotechnology offers great promise for the diagnosis and treatment of a number of clinical conditions. The work we are doing within this project, as well as more broadly across the University, will facilitate the translation of these novel technologies to clinical studies and beyond.”

The SAFE-N-MEDTECH project is part of the Open Innovation Test Bed (OITB) initiative from the European Commission, representing an investment of £15.8m over four years.